OPKO Health (NASDAQ:OPK) Earns “Buy” Rating from HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $3.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 96.72% from the stock’s previous close.

Several other research analysts have also recently issued reports on the stock. Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

OPKO Health Trading Down 1.6 %

Shares of OPKO Health stock traded down $0.03 on Monday, hitting $1.53. 3,160,008 shares of the company traded hands, compared to its average volume of 4,017,459. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.02 billion, a PE ratio of -8.03 and a beta of 1.78. The stock’s 50 day moving average price is $1.69 and its 200-day moving average price is $1.58. OPKO Health has a 52 week low of $1.15 and a 52 week high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. Equities research analysts predict that OPKO Health will post -0.25 EPS for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $1.74 per share, with a total value of $348,000.00. Following the completion of the transaction, the chief executive officer now owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have purchased 1,214,971 shares of company stock worth $1,913,692 over the last quarter. Insiders own 49.69% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in OPK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in OPKO Health by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 8,064 shares in the last quarter. Two Sigma Advisers LP boosted its stake in OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares in the last quarter. FMR LLC grew its position in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,417 shares in the last quarter. Finally, Comerica Bank raised its holdings in shares of OPKO Health by 18.2% in the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after buying an additional 16,369 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.